BUY
Was upgraded today. He regrets not owning it. Great managers. Owning a biotech ETF like XBI is fine for risk management. Healthcare is recession-resistant and he loves it.
Pharma & Healthcare
HOLD
She wishes that today's upgrade had come earlier. 2023 earnings will be flat, not great, but they have some new drugs will drive earnings in the future. This stock could do nothing for a while, but nothing wrong to hold it; earnings may stay flat.
Pharma & Healthcare
STRONG BUY
His favourite stock in his favourite sector. It is up 18% YTD.
Pharma & Healthcare
BUY
It trades at 13x earnings. Their pipeline is really good but was under pressure given drug pricing issues. This has outperformed the market this year. They have a strong pipeline of drugs and trades at an attractive valuation.
Pharma & Healthcare
BUY
Healthcare is his biggest sector. HC is seeing the classic shift to defensives as inflation peaks. Also, HC trades at only 18x while utilities and staples trade at 21x, so it's the cheapest defensive. He owns Pfizer, UNH and Regeneron.
Pharma & Healthcare
HOLD
Large cap biotech. Its two franchises are dominant: macular degeneration and atopic dermatitis. One of the best at R&D. Proven ability to execute. One of the better growth profiles for next 3-5 years. Bit of volatility around reimbursement. Decent valuation. No dividend.
Pharma & Healthcare
COMMENT
They report Friday. Sells at 11x earnings. They have drugs for asthma and other illnesses.
Pharma & Healthcare
BUY
On Monday, they host an investors' event to showcase their work in RNA-based therapies and gene editing. Though it's a biotech, REGN is profitable and trades at a low PE. It trades on earnings and not future sales. If they tell a great story next week, he expects this stock to break out to an all-time high.
Pharma & Healthcare
BUY
Not only REGN, but all healthcare stocks, like Bristol-Myers and Merck, have been under pressure. REGN is a great stock and worth holding long-term.
Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Nov 23/20, Up 9.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with REGN has triggered its stop at $565. To remain disciplined, we recommend covering the position at this time. Combined with the previous recommendation to cover half the position, this results in a net investment gain of 15%.
Pharma & Healthcare
BUY
It hit a new 52-week high today, based on it successful Covid treatment that gets patients out of the hospital a lot faster.
Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Nov 24/20, Up 22.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with REGN has achieved its $630 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $425) to $565.
Pharma & Healthcare
COMMENT
They developed a Covid treatment drug, but Washington has been unkind to them and made it inaccessible to the public. A great company, but it can't work for free.
Pharma & Healthcare
HOLD
It confuses him. They produce great drugs and are run by a fine CEO, but they aren't making a lot of money on their Covid cocktail. The stock has been struggling, but he would not sell.
Pharma & Healthcare
BUY on WEAKNESS
Buy it under $500. It hasn't been in the news lately. They have a great Covid drug, but aren't making enough of it.
Pharma & Healthcare
Showing 1 to 15 of 23 entries

Regeneron Pharmaceuticals Inc(REGN-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 4

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 6

Stockchase rating for Regeneron Pharmaceuticals Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Regeneron Pharmaceuticals Inc(REGN-Q) Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc stock symbol?

Regeneron Pharmaceuticals Inc is a American stock, trading under the symbol REGN-Q on the NASDAQ (REGN). It is usually referred to as NASDAQ:REGN or REGN-Q

Is Regeneron Pharmaceuticals Inc a buy or a sell?

In the last year, 6 stock analysts published opinions about REGN-Q. 4 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Regeneron Pharmaceuticals Inc.

Is Regeneron Pharmaceuticals Inc a good investment or a top pick?

Regeneron Pharmaceuticals Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Regeneron Pharmaceuticals Inc.

Why is Regeneron Pharmaceuticals Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Regeneron Pharmaceuticals Inc worth watching?

6 stock analysts on Stockchase covered Regeneron Pharmaceuticals Inc In the last year. It is a trending stock that is worth watching.

What is Regeneron Pharmaceuticals Inc stock price?

On 2023-01-27, Regeneron Pharmaceuticals Inc (REGN-Q) stock closed at a price of $742.83.